Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Antonia, Scott Joseph
  • Gettinger, Scott N
  • Chow, Laura Quan Man
  • Juergens, Rosalyn
  • Borghaei, Hossein
  • Shen, Yun
  • Harbison, Christopher
  • Chen, Allen C
  • Ready, Neal
  • Rizvi, Naiyer A

publication date

  • May 20, 2014